Total subjects (N) | 236 |
---|---|
Age, mean ± SD | 70.4 ± 5.9 |
Non-Hispanic white, n (%) | 236 (100) |
Male gender, n (%) | 123 (52.1) |
BMI, mean ± SD | 28.4 ± 4.5 |
Pack years, median (IQR) | 48 (37.5–70) |
Current smoker, n (%) | 74 (31.4) |
FWS, median (IQR) | 3 (2.0 to 3.5) |
Wrinkled, n (%) | 46 (19.5) |
VE, median (IQR) | 2.5 (1.8 to 3.4) |
FEV1% predicted, mean ± SD | 82.6 ± 22.4 |
FEV1/FVC%, mean ± SD | 67.7 ± 13.3 |
FEV1/FVC < 70%, n (%) | 113 (47.9%) |
GOLD stage, n (% of total N) | |
0 (Non-obstructed) | 123 (52.1%) |
I | 31 (13.2%) |
II | 23 (9.8%) |
III | 36 (15.3%) |
IV | 20 (8.5%) |
DLCO % predicted, mean ± SD | 67.2 ± 18.0 |
RV % predicted, mean ± SD | 120.5 ± 33.8 |
RV/TLC %, mean ± SD | 44.2 ± 9.0 |
Visual emphysema, n (%) | 130 (55.1%) |
%LAA, mean ± SD | 4.0 ± 8.2 |
Perc15, mean ± SD | − 910.9 ± 26.9 |